News for ChemoCentryx, Inc. (CCXI)

PR NewswireTHOUSAND OAKS, Calif., March 4, 2025 THOUSAND OAKS, Calif., March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of

PR NewswireTHOUSAND OAKS, Calif., March 1, 2025 Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in

PR NewswireTHOUSAND OAKS, Calif., Dec. 7, 2024 Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%THOUSAND OAKS, Calif., Dec. 7, 20

BLINCYTO ® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

PR NewswireTHOUSAND OAKS, Calif., Dec. 5, 2024 Investment Establishes Second Facility in Holly Springs; Builds on Previous $550M CommitmentTHOUSAND OAKS,

PR NewswireTHOUSAND OAKS, Calif., Dec. 2, 2024 THOUSAND OAKS, Calif., Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global H

PR NewswireTHOUSAND OAKS, Calif., Nov. 29, 2024 THOUSAND OAKS, Calif., Nov. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7th Annual Eve

PR NewswireTHOUSAND OAKS, Calif., Nov. 26, 2024 MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Li

PR NewswireTHOUSAND OAKS, Calif., Nov. 26, 2024 THOUSAND OAKS, Calif., Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the

PR NewswireTHOUSAND OAKS, Calif., Nov. 20, 2024 Howard Chang, M.D., Ph.D., Joins as Senior Vice President of Research and Chief Scientific OfficerTHOUSAND

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that...

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data...

Amgen stock (NASDAQ: AMGN) has seen a 17% rise in a month, outperforming the broader S&P500 index, up 1%.

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023. The dividend...

GuruFocus Article or News written by insider and the topic is about:

George Soros portfolio, holdings, 13F and news. Updated: 2023-02-13

GuruFocus Article or News written by insider and the topic is about: